Fellowship · Cincinnati, OH
Sponsored by Cincinnati Children's Hospital Medical Center
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.
Pediatric neurology · 2021 · 553 citations · John Bissler
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 399 citations · Deepa Chand
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2.
Kidney international reports · 2021 · 245 citations · Prasad Devarajan
Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies.
The Journal of clinical investigation · 2024 · 115 citations · Lawrence Shoemaker
Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association.
Hypertension (Dallas, Tex. : 1979) · 2022 · 162 citations · Mark Mitsnefes
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Journal of hepatology · 2021 · 248 citations · Deepa Chand
Use Of Area-Based Socioeconomic Deprivation Indices: A Scoping Review And Qualitative Analysis.
Health affairs (Project Hope) · 2022 · 139 citations · Meera Kotagal
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 228 citations · Deepa Chand